Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in a Phase I clinical trial in Australia for its innovative drug, LM-350, a CDH17 antibody-drug conjugate developed by its subsidiary, LaNova Medicines. This marks a significant step in the clinical development of LM-350, which targets gastrointestinal tumors with high CDH17 expression, addressing unmet clinical needs in cancers such as colorectal, gastric, pancreatic, and esophageal. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of LM-350, with hopes of advancing treatment options for patients with advanced solid tumors.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands that operates in the biopharmaceutical industry. It focuses on the development of innovative drugs, particularly in the area of antibody-drug conjugates (ADCs) for cancer treatment.
Average Trading Volume: 173,134,055
Technical Sentiment Signal: Buy
Current Market Cap: HK$143.1B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.